Evidence-Based Lymphoedema Risk Reduction: What’s Changed and What Matters
The National Lymphedema Network (NLN) has released its updated Position Paper on Evidence-Based Practices for Lymphedema Risk Reduction (March 2026), offering a timely shift toward more nuanced, evidence-informed guidance for clinicians and patients.
This update reflects over a decade of emerging research and signals an important move away from overly cautious, blanket restrictions toward individualised, risk-stratified care.
Moving Beyond Blanket Precautions
One of the most notable updates is the clarification around commonly restricted procedures.
- Blood pressure, injections, and venipuncture in the at-risk limb
→ Not associated with increased swelling in prospective studies for those at risk - Emphasis is now on informed, shared decision-making, rather than strict avoidance
This represents a meaningful shift for clinicians supporting patient confidence and reducing unnecessary fear.
The Central Role of Prospective Screening
The paper strongly reinforces prospective surveillance as best practice:
- Baseline (pre-operative) measurement where possible
- Regular, risk-stratified follow-up (e.g. every 3 months for high risk early post-op)
- Use of combined approaches:
- Objective measures (volume, bioimpedance)
- Symptom reporting
- Clinical assessment
Early identification remains critical, with clear evidence that earlier diagnosis leads to better outcomes.
Compression: Targeted, Not Universal
The updated guidance takes a more selective approach to compression:
- Prophylactic compression
→ May delay or reduce onset in high-risk individuals (e.g. axillary node dissection) - Not routinely recommended for all (e.g. air travel alone is not a risk factor)
- Emphasis on proper fitting and clinical oversight
This reinforces the importance of clinical reasoning over routine prescription.
Exercise and Activity: Stronger Reassurance
The paper continues to support a growing evidence base:
- Progressive, individualised exercise does not trigger lymphedema in those at risk
- Exercise is beneficial for those with lymphedema
This helps reframe activity as part of prevention and management, rather than a risk.
Skin Care and Infection: A Critical Priority
A consistent and strongly reinforced message:
- Cellulitis significantly increases risk of development and progression
- Skin care is not optional — it is foundational
- Early antibiotic treatment for suspected infection is essential
This remains one of the most clinically actionable areas for both prevention and long-term management.
Weight and Comorbidities Matter
The update highlights:
- Obesity as a major modifiable risk factor
- The need for multidisciplinary support (nutrition, exercise, medical input)
This reinforces that lymphedema risk is not isolated, but part of broader health context.
A More Balanced View of Risk
Several long-held assumptions are reconsidered:
- Air travel → not shown to increase risk
- Heat exposure → may cause temporary changes, but not clearly linked to progression
- Greater focus on actual evidence vs historical caution
Surgical Advances and Prevention
Emerging approaches are acknowledged:
- Axillary reverse mapping (ARM) and
- Immediate lymphatic reconstruction (LYMPHA)
These show promise in reducing incidence, though ongoing research is needed .
What This Means for Practice
This updated position paper supports a clear direction for clinicians:
- Move from restriction-based advice → risk-informed guidance
- Prioritise early detection and surveillance systems
- Support patient confidence, autonomy, and understanding
- Maintain focus on skin care, infection prevention, and weight management
- Use compression and precautions selectively, not routinely
Above all, it reinforces the role of the clinician in interpreting evidence within the individual context of each patient.
